Taiyo Yakuhin Of Japan Secures Inventories To Ensure Stable Supply
This article was originally published in PharmAsia News
To prepare for upcoming changes in Japan's prescription drug forms, and anticipated increased competition in the generic drug business as a result of the change, Japanese generic drug giant, Nagoya-based Taiyo Yakuhin Co., announced it has secured a manufacturing inventory of seven and a half months and a retail inventory slightly over one and a half months of its 524 drug items. The move is also a follow up to Japan's Ministry of Health, Labor and Welfare's request of generic drug makers to secure a month's worth of both inventories. (Click here for more - Japanese language)
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.